In 1953, the U.S. Food and Drug Administration recognized EDTA (ethylene diamine tetra acetic acid , a synthetic amino acid) as a treatment for lead toxicity. Some patients who also happened to suffer from cardiac disease had unexpected improvement in their angina symptoms during lead poisoning detoxification treatments with EDTA. Since that time, numerous studies by investigative physicians have been published documenting the possible effectiveness of EDTA for treatment of arthersclerosis, arthersclerotic arterial disease and age-related degenerative diseases. Clinical practice has proven that no serious adverse effects have been experienced when Chelation was administered following the recommended protocol.

The presence of heavy metals in the blood steam can cause an increased production of free radicals (highly active molecular fragments). When out of control the free radicals can cause damage to surrounding tissue, triggering or aggravating various medical conditions.

Following a recommended protocol, EDTA is administered intravenously, usually over a 2 1/2 to 3 hour period. The Chelation drip includes the addition of vitamins and minerals.

Chelation patients are advised to take a comprehensive approach to their treatment and health, including diet, exercise, stress management programs and dietary supplements.

                                          Back